What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc., nothing.
The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.
Study outcome won't sway company on eye drug
Roughly 23 million more people would be uninsured over a decade if the House-passed Republican Obamacare...
Study shows so-called "light" cigarettes do not benefit health and may contribute to the increased risk...
A new survey found that when it comes to recreational drug use, magic mushrooms appear to...
President Donald Trump’s administration announced the details Monday of the president’s unprecedented international anti-abortion policy, which...
